多西他赛联合卡铂一线治疗老年晚期非选择性非小细胞肺癌临床观察

目的观察多西他赛联合卡铂一线治疗老年晚期表皮生长因子受体（EGFR）突变状况不明（非选择性）非小细胞肺癌（NSCLC）的疗效和毒性反应。方法老年晚期非选择性NSCLC患者共46例,多西他赛用量60 mg/m2,第1天静脉滴注,卡铂AUC=4,第2天静脉滴注。21~28 d为1个周期,每例患者至少接受2个周期治疗。结果 46例患者均可评价疗效,完全缓解（CR）1例,部分缓解（PR）21例,稳定（SD）19例,进展（PD）5例,总有效率为47.87%（22/46）,其中位疾病进展时间为（TTP）5.61个月,中位生存时间（MST）13.21个月（3~20个月）,1年生存率为49.21%。主要毒副反应为白细胞下降、骨关节痛、指端麻木、脱发等,积极治疗能控制。结论多西他赛联合卡铂一线治疗老年晚期非选择性NSCLC安全、有效。

The clinical observation of first-line docetaxel and carboplatin treatment for elderly patients with non-selective non-small-cell lung cancer

Objective To observe the efficacy and toxicity of first-line docetaxel and carboplatin treatment for elderly patients with epidermal growth factor receptor（EGFR） or unmutated（non-selective） non-small-cell lung cancer（NSCLC）.Methods The study included 46 elderly patients with advanced non-selective NSCLC.The dosage of docetaxel was 60 mg/m2,on day 1,carboplatin AUC=4,on day 2,21-28 d as a therapueutic cyle.Each patient received at least 2-cycle therapy.Results Forty-six patients were evaluable for efficacy.Complete remission（CR） was seen in 1 case,partial remission（PR） in 21 cases,stable（SD） in 19 cases and progress（PD） in 5 cases were reported.The overall efficacy rate was 47.87%（22/46）,in which median time to progression（TTP） was 5.61 months,median survival time（MST） was 13.21 months（3 to 20 months）,and 1 year survival rate was 49.21%.The main side effects were leukopenia,bone and joint pain,finger numbness,hair loss,and they can be controlled with active treatment.Conclusion First-line docetaxel and carboplatin treatment of advanced non-selective NSCLC is safe and effective.